Novostia is pioneering a new generation of artificial heart valves, specifically designed to address significant unmet medical needs globally. Their Triflo valve boasts several advanced features, including low thrombogenicity, lifelong durability, and a low acoustic signature, making it suitable for patients of all ages, including children. The technology is still investigational and has not yet received approval for commercial sale. The company emphasizes the potential of the Triflo valve to significantly benefit thousands of patients annually, particularly young individuals, as highlighted by endorsements from leading medical professionals.

The development of the Triflo valve has been supported by extensive preclinical research, including rigorous in-vitro and in-vivo testing. This research has been conducted in collaboration with prestigious institutions and experts in aeronautics, medicine, and science. The valve's design has undergone thorough validation through state-of-the-art experimental and numerical testing, focusing on hydrodynamic performance, structural integrity, and durability. Independent institutes, such as Bern University and the California Institute of Technology, have contributed to the extensive comparative testing, which has demonstrated promising safety and effectiveness outcomes, including successful long-term implantation without the need for anticoagulants.

Switzerland

Novostia is a privately held medical device company developing an innovative artificial heart valve, designed for patients of any age, including children.

Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease. 

For more information please visite www.novostia.com

Novostia

Company Details